Antiphospholipid Antibodies and Platelets

Chong, Beng H.; Brighton, Timothy; Chesterman, Colin N.

doi:10.1055/s-2007-1000381

Cited by 23 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After being centrifuged twice at 4000 g for 20 min at 4ЊC, platelet-poor plasma was immediately used in coagulation assays. A phospholipid-dependent inhibitor of coagulation was diagnosed in the patient's plasma when the activated partial thromboplastin time (aPTT) was prolonged and was not corrected by mixing the patient's plasma with normal pooled plasma (vol:vol) (Chong et al, 1995). The diluted prothrombin time and the Staclot LA ® test (Stago Diagnostica, Asnières, France) were used as confirmatory tests.…”

Section: Platelet Count Blood Was Drawn Into Edta (Potassium Salt) Imentioning

confidence: 99%

Anti‐platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia

et al. 1997

View full text Add to dashboard Cite

Summary. The role of antiphospholipid antibodies in the pathogenesis of the thrombocytopenia observed during primary antiphospholipid antibody syndrome (APAS) and systemic lupus erythematosus (SLE) remains controversial. We have used the MAIPA test to examine the frequency and specificity of anti-platelet antibodies directed against the major platelet membrane glycoproteins (GP IIb-IIIa, GP Ib-IX, GP Ia-IIa and GP IV) in patients where SLE and APAS were associated or not with thrombocytopenia. Results were compared with a series of 26 ITP patients, 46% of whom were shown to possess anti-platelet antibodies directed against one or more of the platelet surface glycoproteins. When APAS was associated with thrombocytopenia, 7/10 patients possessed antibodies against GP IIb-IIIa and/or GP Ib-IX. For SLE patients with thrombocytopenia, 6/10 patients were shown to have antiplatelet antibodies against GP IIb-IIIa, GP Ib-IX or GP IV. In contrast, for APAS (n¼11) and SLE patients (n¼11) without thrombocytopenia, only one patient had an antibody directed against GP IIb-IIIa and one patient had an antibody to GP IV. Our results suggest that antibodies directed against major platelet membrane glycoproteins may play a role in the thrombocytopenia that is seen during SLE and APAS.

show abstract

Section: Platelet Count Blood Was Drawn Into Edta (Potassium Salt) Imentioning

confidence: 99%

Anti‐platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia

et al. 1997

View full text Add to dashboard Cite

show abstract

“…The latter are more closely associated with thromboembolic disease. (b) About 20% of patients with lupus anticoagulants are thrombocytopenic [17,20], and many patients with antiphospholipid antibodies have platelet-reactive antibodies [2,6,8,10,17,20,21]. Thus, these antibodies could be involved in an immunomediated platelet destruction.…”

Section: Introductionmentioning

confidence: 99%

Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome

Panzer

Gschwandtner

Hütter

et al. 1997

Annals of Hematology

View full text Add to dashboard Cite

We have studied target platelet antigens in 22 patients with lupus anticoagulants and a primary antiphospholipid syndrome in order to determine whether any specificities of platelet autoantibodies are correlated with thromboembolism, and if these antibodies cross-react with phospholipids, which would suggest their role in the development of thromboembolic disease. Platelet counts were median 203 x 10(9)/l, range 100-298 x 10(9)/l. Platelet antibodies were found in six thrombocytopenic patients and in further nine patients. All these 15 patients had antibodies against GPIIb/ IIIa, five patients against GPIb/IX, and six patients against GPIV. Anti-GPIb/IX and -GPIV occurred only in combination with anti-GPIIb/IIIa antibodies. There was no correlation between the presence of detectable platelet antibodies or any of their glycoprotein specificity and thrombocytopenia or the history of a thromboembolic disease. Eluates from platelets contained only GPIIb/IIIa reactivities, but neither anti-GPIb/IX nor anti-GPIV. None of the eluates contained lupus anticoagulant activity. In one case, the platelet eluates contained anti-GPIIb/IIIa and anticardiolipin IgG antibodies. These results suggest that in patients with a primary antiphospholipid syndrome the presence of platelet autoantibodies neither indicate a risk for thromboembolic disorder nor have lupus anticoagulant activity.

show abstract

“…Anti-2GPI antibodies are associated with thrombocytopenia [21,22,37]. These antibodies recognize soluble 2GPI with low affinity.…”

Section: Discussionmentioning

confidence: 99%

Anti-β2 Glycoprotein I Antibodies Prevent the De-activation of Platelets and Sustain their Phagocytic Clearance

Bondanza

Sabbadini

Pellegatta

et al. 2000

Journal of Autoimmunity

View full text Add to dashboard Cite

Antiphospholipid Antibodies and Platelets

Cited by 23 publications

References 45 publications

Anti‐platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia

Anti‐platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia

Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome

Anti-β2 Glycoprotein I Antibodies Prevent the De-activation of Platelets and Sustain their Phagocytic Clearance

Contact Info

Product

Resources

About